Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (?Iressa?) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells-Reference-Cited by-同舟云学术

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (?Iressa?) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells

Published:2004 Issue:1 Volume:201 Page:97-105
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Sgambato Alessandro,Camerini Andrea,Faraglia Beatrice,Ardito Raffaele,Bianchino Gabriella,Spada Daniele,Boninsegna Alma,Valentini Vincenzo,Cittadini Achille

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference46 articles.

1. Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

2. Flutamide

3. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

4. p53 oncogene mutations in three human prostate cancer cell lines

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Therapy Resistance to Targeted Therapies in Prostate Cancer;Frontiers in Oncology;2022-05-24

2. A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC);EBioMedicine;2021-02

3. Long non‐coding RNA FAM66C is associated with clinical progression and promotes cell proliferation by inhibiting proteasome pathway in prostate cancer;Cell Biochemistry and Function;2020-05-19

4. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers;Journal of Bone Oncology;2015-03

5. Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells;PLoS ONE;2013-12-05